<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914913</url>
  </required_header>
  <id_info>
    <org_study_id>CSCC/BMRP/2013//01</org_study_id>
    <nct_id>NCT01914913</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa</brief_title>
  <official_title>An Open Labeled Clinical Study to Evaluate the Safety and Efficacy OF Autologous Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Retinitis Pigmentosa. It is Self Funded (Patients' Own Funding) Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chaitanya Hospital, Pune</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chaitanya Hospital, Pune</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retinitis pigmentosa is an eye disease in which there is damage to the retina. The retina is
      the layer of tissue at the back of the inner eye that converts light images to nerve signals
      and sends them to the brain.Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs) is
      used for this condition .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will involve about 8 visits over 1Â½ years .Each participant will be enrolled in
      study as per inclusion and exclusion criteria .Informed consent will be taken from subject
      before including in study. Subject will be underwent for specific tests of the participant's
      vision and health. These visits may include visual exams, blood draw for laboratory testing,
      brief medical history and exam, and occasionally a questionnaire (survey), in addition to the
      visit for the surgical procedures. The primary outcome for this study will be a visual acuity
      score after one year of stem cell therapy .

      Follow-up visits will be required regularly to determine the effectiveness of Autologous Bone
      Marrow derived Mono Nuclear Stem Cell (BMMNCs) in RP.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual acuity</measure>
    <time_frame>1 YEAR</time_frame>
    <description>Electronic Visual Acuity (EVA) technology</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>BMMNCs</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>BMMNCs</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMMNCs</intervention_name>
    <description>Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval ,transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)</description>
    <arm_group_label>BMMNCs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65

          -  Diagnosis of retinitis pigmentosa

          -  willingness to undergo Bone marrow and umbilical cord derived Mesenchymal stem cell
             transplantation.

          -  To give an informed consent as well as sign the required Informed Consent Form (ICF)
             for the study.

          -  willingness to regularly visit the hospital / clinic for follow up during the follow
             up period / on prior agreed time points as per the protocol.

        Exclusion Criteria:

          -  Positive test results for HIV and AIDS complex ,HCV (hepatitis C virus ), HbsAg and
             Syphilis

          -  Women who are pregnant or lactating

          -  Complications of diabetic retinopathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ANANT E BAGUL, MS ORTHO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaitanya Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sachin P Jamadar, D.Ortho</last_name>
    <phone>918888788880</phone>
    <email>sac2751982@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chaitanya Hospital</name>
      <address>
        <city>Pune,</city>
        <state>Maharashtra</state>
        <zip>411030</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sachin P Jamadar, D ORTHO</last_name>
      <phone>+918888788880</phone>
      <email>sac2751982@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anant E Bagul, MS,Ortho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2013</study_first_submitted>
  <study_first_submitted_qc>August 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <last_update_submitted>September 16, 2014</last_update_submitted>
  <last_update_submitted_qc>September 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chaitanya Hospital, Pune</investigator_affiliation>
    <investigator_full_name>Dr. Sachin Jamadar</investigator_full_name>
    <investigator_title>Co -investigator</investigator_title>
  </responsible_party>
  <keyword>retinitis pigmentosa</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>stem cell</keyword>
  <keyword>BMMNC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

